The Evolving Treatment Algorithm for Advanced Neuroendocrine Neoplasms: Diversity and Commonalities Across Tumor Types

ANDREW E. HENDIFAR,a DEEPTI DHALL,a JONATHAN R. STROSBERGb

aDepartment of Medicine and Pathology, Cedars-Sinai Medical Center, Los Angeles, California, USA; bH. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA

Disclosures of potential conflicts of interest may be found at the end of this article.

Key Words. Neuroendocrine • Carcoid • Gastrointestinal • Lung • Pancreas

ABSTRACT

Neuroendocrine neoplasms (NEN) most commonly arise in the gastroenteropancreatic system and lungs. The incidence of NEN is increasing globally, with improved diagnostic techniques identifying patients with early-stage disease. The number of approved therapies for the treatment of advanced disease has grown substantially in the past decade. The treatment algorithm for advanced NEN is evolving from one that is directed by primary site specific classification to one that is directed by biologic classification, as evidenced by overlapping systemic treatments across the primary tumor sites. Commonalities in biologic characteristics across primary sites include functional status, differentiation status, grade, level of somatostatin receptor expression, and genetic alterations. In this review, we discuss current clinical evidence and available therapies for the treatment of advanced NEN and highlight the need for prospective trials in patients with well-differentiated, high-grade NEN. The Oncologist 2019;24:54–61

Implications for Practice: This review raises awareness of the evolution of the treatment algorithm for advanced neuroendocrine neoplasms (NEN) from one that is directed by primary tumor site–specific classification to one that is directed by biologic classification. In addition, this review promotes understanding of the new pathologic category of well-differentiated G3 pancreatic neuroendocrine tumors and highlights the need for prospective trials in this patient population, for whom there is currently no standard of care. This review further provides a conceptual treatment schematic that categorizes the recommendations for systemic treatments for advanced disease by biologic classification, including the new and established categories of NEN.

INTRODUCTION

Neuroendocrine neoplasms (NEN) most commonly arise in the gastroenteropancreatic (GEP) system and lungs [1,2]. The term NEN encompasses both well-differentiated (WD) neuroendocrine tumors (NET) and poorly differentiated (PD) neuroendocrine carcinomas (NEC). Many symptoms associated with NEN are nonspecific, such as abdominal pain, diarrhea, flushing, and bowel obstruction, which may lead to delays in diagnosis [3]. The rates of NEN diagnosed each year have increased steadily since the early 1970s [1,2,4], possibly as a result of improvements in diagnostic techniques and the increased detection of asymptomatic early-stage disease [1].

NEN are currently classified by functional status, tumor cell differentiation and grade, somatostatin receptor (SSTR) expression, and, more recently, their genetic alterations. In this review, we present recent epidemiologic data and summarize the biologic characteristics of NEN. We also review pivotal clinical evidence regarding systemic treatments for advanced disease and provide a conceptual schematic of systemic treatments based on tumor classification for advanced NEN.

Epidemiology

Recent estimates of the incidence and prevalence of NEN in the United States are based on nationally representative data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database, which includes comprehensive data from 64,971 patients diagnosed with NEN between 1973 and 2012 (excluding small-cell lung carcinoma [SCLC] and large-cell neuroendocrine carcinoma [LCNEC] of the lung, pheochromocytoma, paraganglioma, and medullary carcinoma of the thyroid) [1,5].
Although the total incidence of malignant neoplasms has remained relatively stable over the past 40 years, the incidence of NEN has increased—by 6.4-fold between 1973 and 2012, from 1.09 to 6.98 per 100,000 persons [1]. This increase in incidence occurred across all sites and stages, although localized disease was markedly increased, from 0.21 to 3.15 per 100,000 persons [1]. The greatest increases in incidence for individual primary tumor sites occurred in the stomach (15-fold) and rectum (9-fold); the increased incidence at these sites may be associated with the increased use of endoscopic procedures in clinical practice [1]. The prevalence of NEN has also increased significantly in the past 20 years, from 0.006% in 1993 to 0.048% in 2012, which may be explained by the increased incidence of NEN and the increased diagnosis of early-stage disease [1]. For NEN diagnosed in the U.S. between 2000 and 2012, the highest incidences were for lung carcinoid tumors (1.49 per 100,000 persons), gastroenteropancreatic (GEP) sites (3.56 per 100,000), and unknown primary site (0.84 per 100,000) [1]. The small intestine (1.05 per 100,000 persons) and rectum (1.04 per 100,000) were the most common GEP primary sites, and the pancreas had an incidence of 0.48 per 100,000 [1].

**Survival**

Recent epidemiologic analyses of SEER data have demonstrated a decreased risk of death for those diagnosed with NEN from 2005 to 2012 versus those diagnosed from 2000 to 2004 in the U.S. [1]. Those diagnosed between 2005 and 2008 had a 17.1% lower risk of death (hazard ratio [HR] = 0.83, 95% confidence interval [CI] = 0.78–0.89), and those diagnosed in the 2009–2012 period had a 21.3% lower risk of death (HR = 0.79, 95% CI = 0.74–0.85). This improvement in survival for patients with NEN of all grades/stages in recent years may be due to increased diagnosis of more indolent NEN identified by improved imaging procedures, which would have previously gone undetected until a later stage [1]. Decreased risk of death was particularly notable \( p < .001 \) vs. 2000–2004) in the subgroup with metastatic gastrointestinal (GI) NEN (2009–2012: HR = 0.71, 95% CI = 0.63–0.82) and metastatic pancreatic NEN (2009–2012: HR = 0.56, 95% CI = 0.44–0.71). Improvement in survival for patients with metastatic NEN likely reflects improvements in therapies [1].

**Functional Status**

Neuroendocrine cells can produce a variety of amine and peptide secretory products, which may produce clinical syndromes in NEN [6]. Classification of NEN as functional or nonfunctional is based on the presence or absence of symptoms related to these hypersecretory syndromes [7].

Carcinoid syndrome results from hypersecretion of vasoactive amines, including serotonin, histamine, tachykinins, and prostaglandins [7]. The cardinal features of carcinoid syndrome are diarrhea (frequency 60%–80%) and flushing (frequency 60%–85%), and a severe complication of carcinoid syndrome is carcinoid heart disease (frequency ≤20%). Carcinoid syndrome is a common functional syndrome in WD-NET originating in the ileum [8]. A recent analysis of the SEER registry linked with Medicare claims data identified 1,786 patients diagnosed with both NET and carcinoid syndrome between 2000 and 2011 in the United States; 19% of these patients received a diagnosis of carcinoid syndrome within 6 months of being diagnosed with NET [9]. Carcinoid syndrome was most common in patients with WD G1/2, distant metastatic disease originating in the small intestine (56%; 242/436) or the cecum (52%; 28/54).

Carcinoid syndrome occurring in patients with a pancreatic primary tumor is very rare [10], owing to the absence of serotonin-producing cells in the normal pancreas [9]. Common functional syndromes occurring in pancreatic NET are insulinoma and Zollinger-Ellison syndrome [10]. Although the majority (70%) of Zollinger-Ellison syndrome cases have a duodenal primary tumor location, 25% are associated with a pancreatic primary [10]. Less common functional syndromes include VIPoma, glucagonoma, and somatostatinoma, named after the biologically active peptide that is secreted [10]. In recent studies, between 60% and 90% of pancreatic NEN have been classified as nonfunctional [10,11]. SEER data analyzed from 1973 to 2000 demonstrated that only 10% (137/1483) of pancreatic NEN were functional, and this frequency did not increase in metastatic disease (8.4%; 75/893) [12].

**Cell Differentiation and Grading**

Grading of GEP NEN is assessed by mitotic rate and/or Ki-67 index [13]. According to the World Health Organization (WHO) classification, NEN are separated into WD and PD tumors based on their cell morphology [13,14]. PD tumors are further classified as small-cell or large-cell morphology [13]. Previously, the differentiation of GEP NEN was assumed to be directly correlated with grade—all low- to intermediate-grade (G1 or G2) NEN were classified as WD-NET, and all high-grade (G3) NEN were classified as PD-NEC [13]. However, G3 NEN are now known to be heterogeneous, comprising both WD-NET with elevated proliferative index (Ki-67 >20%) and PD-NEC (Fig. 1A) [15,16]. Accordingly, a new category of G3 WD-NET has been recognized in the WHO classification of tumors of endocrine organs, which refers specifically to pancreatic NEN [17]. Although these tumors have a somewhat worse prognosis than G2 WD-NET, they are less aggressive than G3 PD-NEC [17]. Distinguishing G3 WD-NET from G3 PD-NEC based on cell morphology can be difficult and may require correlation with clinical history, imaging findings, and molecular phenotype [18,19].

Lung and thymic NEN are currently classified by the WHO classification into four major categories: typical carcinoid (TC; low grade); atypical carcinoid (AC; intermediate grade), SCLC (high grade), and LCNEC (high grade) [20,21]. Key criteria for the differential diagnosis of lung NEN include mitotic rate, necrosis, and Ki-67 index, although the utility of Ki-67 to discriminate TC from AC is not currently established [20]. Ki-67 proliferation indices provided by the classification are as follows: TC, up to 5%; AC, up to 20%; LCNEC, 40%–80%; and SCLC, 50%–100% [20]. Preliminary evidence suggests that lung NEN, like GEP NEN, may
include G3 WD-NET with a Ki-67 index exceeding 20% (or mitotic count >10 per 2 mm²), and these patients have a poorer prognosis than those with G2 WD-NET [22,23].

Preliminary evidence suggests that lung NEN, like GEP NEN, may include G3 WD-NET with a Ki-67 index exceeding 20% (or mitotic count >10 per 2 mm²), and these patients have a poorer prognosis than those with G2 WD-NET.

**SSTR Expression**

SSTRs are highly expressed in NET, with approximately 80% of GEP NET expressing SSTRs [24]. There are five subtypes of SSTR, and the protein/mRNA expression of these SSTRs differ among GEP and lung NET [24,25]. Using receptor subtype antibodies, SSTR2 is expressed by 86% of GEP NET and 40% of lung carcinoids [24,25]. Recent evidence has also demonstrated high expression of SSTR2A in G3 WD-NET (80%), whereas G3 PD-NEC lacks significant expression (16%) [19].

Given the high expression of SSTRs in NET, they are useful for diagnostic imaging. The radioligand ¹¹¹In-pentetreotide binds to SSTR2A and has been the mainstay for diagnostic imaging of NET [26]. This technique has a sensitivity of 60%–80% [26]. Newer SSTR-based positron emission tomography (PET) scans, including ⁶⁸Ga-DOTA-TATE, -TOC, and -NOC, offer substantially higher sensitivity and improved spatial resolution compared with ¹¹¹In-pentetreotide-based somatostatin receptor scintigraphy [27]. ⁶⁸Ga-DOTA PET/computed tomography (CT) has therefore replaced ¹¹¹In-pentetreotide as the method of choice to localize and stage NET, with a sensitivity of 88%–93% and a specificity of 88%–95% [26]. This has resulted in a significantly higher overall accuracy with ⁶⁸Ga-DOTA PET/CT (0.94, 95% CI = 0.89–1.00) versus ¹¹¹In-pentetreotide (0.82, 95% CI = 0.74–0.90) [28].

**Genetic Landscape**

Most NEN are sporadic; fewer than 5% of GEP NEN have inherited mutations [6]. No activating mutations have been identified, with inherited mutations resulting in a loss of tumor suppressor genes. Somatic alterations are identified in 1%–50% of GEP NEN; these typically involve mutations, loss of heterozygosity, and chromosomal changes that lead to activated signaling pathways such as PI3K/AKT/mTOR [6]. In pancreatic NET, the MEN1 gene is somatically inactivated in 45% of patients, alterations in mTOR pathway genes are evident in 15% [17], and loss of DAXX or ATRX occurs in 43% [29]. The loss of DAXX/ATRX is associated with chromosome instability and reduced survival [30]. The genetic alterations in pancreatic PD-NEC are considerably different from those in pancreatic WD-NET; there are often mutations in TP53 and RB1, whereas MEN1, ATRX, and DAXX are not altered [17,31]. Conversely, RB1 and TP53 mutations have not been identified in pancreatic WD-NET [31]. The genetic landscape of pancreatic G3 WD-NET is more similar to that of G1/G2 NET than to PD-NEC [18]. It has been proposed that G3 WD-NET arises from progression of G1/G2 WD-NET and is a biologically different entity from G3 PD-NEC (Fig. 1B) [32]. Differential diagnosis of G3 WD-NET from G3 PD-NEC may be assisted by application of molecular markers TP53, RB1, ATRX, and DAXX [18] in conjunction with Ki-67 proliferation index and SSTR2A expression [19].
Lung carcinoid tumors display a very low somatic mutation rate (0.4 per Mbps), whereas SCLC and LCNEC have the highest rates (>7 per Mbps) in human tumors [20]. TP53 and RB1 mutation and inactivation are rare in TC (<5%) but more frequent in AC (20%). TC and AC may contain MEN1 mutations in sporadic cases (40%). SCLC and LCNEC are driven by inactivating mutations in the RB and TP53 genes and never harbor MEN1 somatic mutations [20]. Although double genetic inactivation of TP53 and RB is universal in SCLC [20], it is not in LCNEC, with TP53 altered in 78% of cases and RB1 in 38% [33]. Current data support the notion that lung carcinoid tumors are genetically distinct from high-grade lung tumors and are therefore not early progenitors of SCLC or LCNEC, whereas TC and AC have no genetic segregation and appear to derive from the same progenitor [20]. Molecular markers for WD G3 lung NET have not been examined at this time.

Pivotal Clinical Evidence: Treatments for Tumor Control in Advanced NET

An overview of the patient characteristics and primary end-point results from each prospective randomized clinical trial are provided in Table 1 [34–40]. Two key studies have demonstrated the antiproliferative effect of somatostatin analogues (SSAs) in advanced GEP NET: PROMID and CLARINET. The PROMID trial showed a significant prolongation in the median time to tumor progression with long-acting octreotide 30 mg every 28 days (q28d) versus placebo (14.3 vs. 6.0 months, HR = 0.34, 95% CI = 0.20–0.59, p = .000072) in patients with midgut NET. Patients with functional or nonfunctional tumors had similar responses, whereas the antiproliferative response was more pronounced in those with a low hepatic tumor load (<10%) (p = .0023) [34]. The CLARINET trial demonstrated a significant prolongation in median progression-free survival (PFS) with lanreotide 120 mg q28d versus placebo (not reached vs. 18.0 months, HR = 0.47, 95% CI = 0.30–0.73, p < .001) [35]. Patients appeared to experience a PFS benefit from lanreotide treatment regardless of hepatic tumor volume or grade. Hazard ratios for disease progression in patients with primary tumor sites in the midgut (0.35, 95% CI = 0.16–0.80) and pancreas (0.58, 95% CI = 0.32–1.04) also appeared to favor lanreotide over placebo; however, the benefit of lanreotide for patients with a hindgut primary NET is unclear due to the small sample size of this subgroup (n = 14) [35].

Sunitinib is approved for the treatment of advanced progressive WD pancreatic NET [41], based on the demonstration of an extended PFS with sunitinib versus placebo (median 11.4 vs. 5.5 months, HR = 0.42, 95% CI = 0.26–0.66, p < .001) [39]. Patients with nonfunctional tumors appeared to experience a greater PFS benefit (HR = 0.26, 95% CI = 0.13–0.54) versus those with functional tumors (HR = 0.75, 95% CI = 0.30–1.84) [39].

Everolimus is approved for the treatment of advanced, progressive, nonfunctional NET of the pancreas, GI tract, and lung [42,43], due to positive results from RADIANT-3 and RADIANT-4; a significant benefit in median PFS was demonstrated with everolimus in patients with advanced progressive pancreatic NET in RADIANT-3 (11.0 vs. 4.6 months, HR = 0.35, 95% CI = 0.27–0.45; p < .001) [37] and in patients with advanced progressive nonfunctional NET of the GI tract or lung in RADIANT-4 (11.0 vs. 3.9 months, HR = 0.48, 95% CI = 0.35–0.67, p < .00001) [38]. In RADIANT-4, the PFS benefit with everolimus compared with placebo was observed regardless of tumor grade or primary site [38]. Furthermore, health-related quality of life was preserved with everolimus treatment versus placebo [44].

RADIANT-2 compared everolimus and placebo, both in combination with long-acting octreotide 30 mg q28d, in patients with progressive, low- or intermediate-grade NET and a history of secretory symptoms attributed to carcinoid syndrome [36]. This trial did not lead to the approval of everolimus plus long-acting octreotide for functional NET. RADIANT-2 demonstrated a PFS benefit with everolimus versus placebo (median 16.4 vs. 11.3 months, HR = 0.77, 95% CI = 0.59–1.00, p = .026); however, the prespecified significance boundary of p = .0246 was not met [36]. A subgroup analysis indicated a potentially higher PFS benefit for everolimus in patients with NET originating in the colon (median 29.9 vs. 13.0 months, HR = 0.39) in comparison with those with NET originating in the small intestine (median 18.6 vs. 14.0 months, HR = 0.77) [36]. A subsequent analysis of the colorectal subgroup (n = 39) in RADIANT-2 confirmed this benefit in patients with hindgut NET, with a significant prolongation in median PFS with everolimus versus placebo (29.9 vs. 6.6 months, HR = 0.34, 95% CI = 0.13–0.89, p = .011) [45]. These findings suggest that the overall PFS benefit provided by everolimus may be lower in patients with slow-growing midgut NET and higher in those with the more aggressive hindgut NET. A RADIANT-4 subgroup analysis also provides support for a higher PFS benefit with everolimus in patients with nonmidgut NET (median 8.11 vs. 1.94 months; HR = 0.27, 95% CI = 0.15–0.51) versus midgut NET (median 17.28 vs. 10.87 months, HR = 0.71, 95% CI = 0.40–1.26) [46]. Importantly, a consistent positive treatment effect of everolimus was demonstrated in the jejunal (median PFS 17.3 vs. 4.5 months, HR = 0.37, 95% CI = 0.08–1.64) but not the ileal subgroup (median PFS 16.6 vs. 16.7 months, HR = 1.22, 95% CI = 0.56–2.65) of the RADIANT-4 trial.

177Lu-Dotatate peptide receptor radionuclide therapy has demonstrated efficacy in many clinical studies of GEP NET in the past decade [47]. 177Lu-Dotatate was recently approved by the European Medicines Agency and the U.S. Food and Drug Administration for advanced GEP NET based on the phase III NETTER-1 trial [40]. Treatment with 177Lu-Dotatate (plus best supportive care of long-acting octreotide 30 mg every 4 weeks [q4w]) resulted in a markedly longer PFS versus the control group (long-acting octreotide 60 mg q4w) in patients with advanced midgut NET and radiologic progression on a standard dose of long-acting octreotide. At the time of data cutoff for the primary analysis, median PFS was not yet reached with 177Lu-Dotatate versus 8.4 months in the control group (HR = 0.21, 95% CI = 0.13–0.33, p < .001) [40]. A single-arm trial of 177Lu-Dotatate in patients with radiologic progression at baseline demonstrated a median PFS of 31 months in patients with pancreatic NET and 29 months in patients with midgut NET [48].
| Characteristic                        | PROMID [34] (n = 85) | CLARINET [35] (n = 204) | RADIANT-2 [36] (n = 429) | RADIANT-3 [37] (n = 410) | RADIANT-4 [38] (n = 302) | Sunitinib phase III [39] (n = 171) | NETTER-1 [40] (n = 229) |
|--------------------------------------|-----------------------|--------------------------|--------------------------|--------------------------|--------------------------|----------------------------------|--------------------------|
| **Tumor grade/differentiation**       |                        |                          |                          |                          |                          |                                  |                          |
| Well-differentiated; 95.3% had Ki-67 ≤2% |                        |                          | Low- to moderately differentiated; 79% (Ki-67 ≤10% to ≤2 mitoses per 10 HPF); 95% had Ki-67 ≤2% | Low- to moderately differentiated (Ki-67 ≤2%); 74% had Ki-67 ≤2%; 69% had Ki-67 ≤2% | Well-differentiated (Ki-67 ≤2%); 74% had Ki-67 ≤2% | Well-differentiated (Ki-67 ≤2%) | Well-differentiated (Ki-67 ≤2%) |
| **Primary sites**                     | Midgut                | Midgut (45%), hindgut (7%), or unknown origin (13%) | Small intestine (52%), lung (10%), colon (7%), pancreas (6%), liver (4%), and other NET sites (21%) | Pancreas                  | Spleen (30%), jejunum/ileum (31%), colon/rectum (15%), unknown origin (12%), and other GI sites | Pancreas                  | Midgut                  |
| **Tumor functional status**           | Functional or nonfunctional; carcinoid syndrome in 38.8% patients | Functional—history of secretory symptoms attributed to carcinoid syndrome | Not specified             | Nonfunctional             | Functional or nonfunctional; functional (26.9%), nonfunctional (50.3%), or not specified (22.8%) | Nonfunctional             | Not specified |
| **SSTR imaging**                      | 74.1% Octreoscan-positive | SRS grade ≥2 (on scale from 0 to 4) | Not specified             | Not specified             | Not specified             | SSTR present on all target lesions using SRS | SSTR present on all target lesions using SRS |
| **Baseline tumor progression**        | Not specified          | Not specified (approximately 5% had baseline tumor progression) | Within 12 months          | Within 12 months          | Within 6 months           | Within 12 months                   | Within 3 years during treatment with long-acting octreotide (20–30 mg q3–4w for at least 12 weeks) |
| **Primary endpoint**                  | Time to tumor progression: median 14.3 months vs. 6.0 months (HR = 0.34; 95% CI = 0.20–0.59; p = .000072) | Progression-free survival: median not reached vs. 18.0 months (HR = 0.47; 95% CI = 0.30–0.73; p = .001) | Progression-free survival: median 16.4 months vs. 11.3 months (HR = 0.77; 95% CI = 0.59–1.00; p = .026 [NS]) | Progression-free survival: median 11.0 months vs. 4.6 months (HR = 0.98; 95% CI = 0.35–0.67; p = .00001) | Progression-free survival: median 11.4 months vs. 5.5 months (HR = 0.02; 95% CI = 0.26–0.66; p < .001) | Progression-free survival: median not reached vs. 8.4 months (HR = 0.42; 95% CI = 0.13–0.33; p < .001) |

Abbreviations: CI, confidence interval; G, grade; GI, gastrointestinal; HPF, high-power field; HR, hazard ratio; NET, neuroendocrine tumors; NS, not significant; q4w, every 4 weeks; q28d, every 28 days; SRS, somatostatin receptor scintigraphy; SSTR, somatostatin receptor.
Treatment with capecitabine combined with temozolomide chemotherapy has shown efficacy in recent retrospective clinical studies of pancreatic NET, with an objective response rate (ORR) ranging from 53% to 70% and a median PFS of 16.5 to >18 months [49]. The efficacy of this treatment approach is undergoing validation in a phase II study of capecitabine + temozolomide versus temozolomide monotherapy in patients with advanced low- to intermediate-grade pancreatic NET (NCT01824875).

PIVOTAL CLINICAL EVIDENCE: TREATMENTS FOR CARCINOID SYNDROME

Long-acting octreotide is approved for the treatment of severe diarrhea and flushing episodes associated with metastatic carcinoid tumors [50], based on the results of the randomized clinical trial by Rubin et al., in which complete (no rescue medication) or partial (rescue medication on ≥2 occasions for ≤5 days) treatment success was demonstrated in 66.7%, 71.4%, and 61.9% of participants treated with long-acting octreotide 10 mg, 20 mg, or 30 mg, respectively [51]. In the recent ELECT clinical trial, lanreotide was found to be effective for the control of carcinoid syndrome symptoms [52]. The adjusted mean percentage of days in which rescue octreotide was used during the 16-week double-blind phase was significantly lower for participants who received lanreotide than for those who received placebo (33.7% vs. 48.5%).

In early 2017, telotristat ethyl was approved for the treatment of carcinoid syndrome diarrhea in combination with SSAs in adults inadequately controlled with SSA therapy alone [53], based on the results of the TELESTAR trial, which assessed the safety and efficacy of telotristat ethyl + SSA therapy in patients with WD metastatic NET and carcinoid syndrome refractory to SSA therapy [54]. Telotristat ethyl at either dose (250 mg t.i.d. or 500 mg t.i.d.) was associated with statistically significant reductions in bowel movement frequency over time compared with placebo; 44% and 42% of participants treated with 250 mg t.i.d. and 500 mg t.i.d., respectively, were classified as responders versus 20% of patients receiving placebo [54].

EVIDENCE FOR TREATMENT OF G3 PD-NEC

Evidence supports the use of platinum-based chemotherapy in the first-line treatment for G3 PD-NEC regardless of primary site. Median PFS with this first-line treatment is approximately 5.0–5.8 months for patients with G3 PD GEP NEC, SCLC, and LCNEC [15,55,56]. The ORR reported with first-line platinum-based chemotherapy is highest in SCLC (~67%) [55] compared with LCNEC (47%) [56] or G3 PD GEP NEC (35%) [15]. However, high disease control rates
specific classification to one that is directed by biologic classification, with overlapping treatments across the primary sites. Commonalities in biologic characteristics across primary tumor sites include functional/nonfunctional status, WD/PD status, high/low grade, SSTR+/SSTR− status, and genetic alterations, with biologic characteristics guiding treatment decisions in some circumstances. It is therefore important to understand the diversity of and commonalities in biologic characteristics across primary tumor sites as the conception of NET continues to evolve, with new classifications and clinical evidence becoming available.

Acknowledgments

Editorial assistance was provided by Harleigh E. Willmott, Ph.D., and Renée Gordon, Ph.D., of ApotheCom (Yardley, Pennsylvania). Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals Corporation.

Author Contributions

Conception/design: Andrew E. Hendifar
Collection and/or assembly of data: Andrew E. Hendifar, Deepti Dhall, Jonathan R. Strosberg
Data analysis and interpretation: Andrew E. Hendifar, Deepti Dhall, Jonathan R. Strosberg
Manuscript writing: Andrew E. Hendifar, Deepti Dhall, Jonathan R. Strosberg
Final approval of manuscript: Andrew E. Hendifar, Deepti Dhall, Jonathan R. Strosberg

Disclosures

Andrew E. Hendifar: Novartis, Ipsen, Perthera, Xbiotech (C/A), Halozyme (travel, accommodations, expenses); Jonathan R. Strosberg: Novartis, AAA (C/A), Ipsen, Lexicon (H). The other author indicated no financial relationships.

(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (C/A) Consulting/advisory relationship; (R) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (O) Ownership interests; (IP) Intellectual property rights/inventor/patient holder; (SAB) Scientific advisory board

CONCLUSION

During recent years, the treatment algorithm for advanced NEN has evolved from one that is directed by primary site-specific classification to one that is directed by biologic classification, with overlapping treatments across the primary sites. Commonalities in biologic characteristics across primary tumor sites include functional/nonfunctional status, WD/PD status, high/low grade, SSTR+/SSTR− status, and genetic alterations, with biologic characteristics guiding treatment decisions in some circumstances. It is therefore important to understand the diversity of and commonalities in biologic characteristics across primary tumor sites as the conception of NET continues to evolve, with new classifications and clinical evidence becoming available.

REFERENCES

1. Dasari A, Shen C, Halperin D et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017;3:1333–1342.
2. Boyar Cetinkaya R, Anees B, Thiis-Evensen E et al. Trends in incidence of neuroendocrine neoplasms in Norway: A report of 16,075 cases from 1983 through 2010. Neuroendocrinology 2017;104:1–10.
3. Strosberg JR, Weber JM, Feldman M, et al. Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors. J Clin Oncol 2012;31:420–425.
4. Ellis L, Shale MJ, Coleman MP. Carcinoid tumors of the gastrointestinal tract: Trends in incidence in England since 1971. Am J Gastroenterol 2010;105:2563–2569.
5. Yao JC, Hassan M, Chua MC et al. One hundred years after “carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063–3072.
6. Kidd M, Modlin IM, Bodei L et al. Decoding the molecular and mutational ambiguities of gastroenteropancreatic neuroendocrine neoplasms: Pathobiology, Cell Mol Gastroenterol Hepatol 2015;1:131–153.
7. Boutzios G, Kaltas G. Clinical syndromes related to gastrointestinal neuroendocrine neoplasms. Front Horm Res 2015;44:40–47.
8. Norheim I, Oberg K, Theodorsson-Norheim E et al. Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg 1987;206:115–1125.
9. Halperin DM, Shen C, Dasari A et al. Frequency of carcinoid syndrome at neuroendocrine tumor diagnosis: A population-based study. Lancet Oncol 2017;18:525–534.
10. Falconi M, Eriksson B, Kaltas G et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors. Neuroendocrinology 2016;103:153–171.
11. Ito T, Igarashi H, Nakamura K et al. Epidemiological trends of carcinoid syndrome and gastrointestinal neuroendocrine tumors in Japan: A nationwide survey analysis. J Gastroenterol 2015;50:58–64.
12. Halfdanarson TR, Rabe KG, Rubin J et al. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 2008;19:1727–1733.
13. Perren A, Coulvelard A, Scoazec JY et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Pathology, Diagnosis and prognostic stratification. Neuroendocrinology 2017;105:936–200.
14. Bosman FT, Carneiro F, Hruban RH et al., eds. WHO classification of tumours of the digestive system. 4th ed. Lyon, France: IARCPress, 2010.
15. Heetfeld M, Chouquet CN, Olsen IH et al. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine tumors. Endocr Rel Cancer 2015;22:657–664.
16. Basturk O, Yang Z, Tang LH et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol 2015;39:683–690.
17. Klöppel G, Couvelard A, Hruban RH et al. Neoplasms of the neuroendocrine pancreas. In: Lloyd RV, Osamura RV, Klöppel G,

© AlphaMed Press 2018
et al., eds. WHO Classification of Tumours of Endocrine Organs. 4th ed. Lyon, France: IARC Press, 2017:209–239.

18. Tang LH, Basturk O, Sue JJ et al. A practical approach to the classification of WHO grade 3 (G3) well-differentiated neuroendocrine tumour (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas. Am J Surg Pathol 2016;40:1192–1202.

19. Konukiewitz B, Schitter AM, Jesinghaus M et al. Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a N67-index above 20. Mod Pathol 2017;30:587–598.

20. Travis WD, Brambilla E, Burke AP et al., eds. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th ed. Lyon, France: International Agency for Research on Cancer, 2015.

21. Travis WD, Brambilla E, Müller-Hermelink HK et al., eds. World Health Organization Classification of Tumours. Pathology & Genetics; Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press, 2004.

22. Kasajima A, Oka N, Ishida H et al. Classification of lung neuroendocrine neoplasms (lung-NENs) according to WHO 2010 for gastroenteropancreatic NENs (GEP-NENs) has prognostic relevance and includes lung-NETS G3. Poster presented at: 12th Annual Conference of the European Neuroendocrine Tumor Society; March 11–13, 2015, Barcelona, Spain.

23. Quinn AM, Chaturvedi A, Nonaka D. High-grade neuroendocrine carcinoma of the lung with carcinoid morphology: A study of 12 cases. Am J Surg Pathol 2017;41:263-270.

24. Baldelli R, Barnabei A, Rizza L et al. Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: Current aspects and new perspectives. Front Endocrinol (Lausanne) 2014;5:7.

25. Kaemmerer D, Specht E, Sänger J et al. Somatostatin receptors in bronchopulmonary neuroendocrine neoplasms: New diagnostic, prognostic, and therapeutic markers. J Clin Endocrinol Metab 2015;100:831–840.

26. Sundin A, Arnold R, Baudin E et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Radiological, nuclear medicine and hybrid imaging. Neuroendocrinology 2017;105:212–244.

27. García-Carbonero R, García-Figueiras R, Carmona-Bayonas A et al. Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Current perspectives and future trends of an exciting field in development. Cancer Metastasis Rev 2015;34:823–842.

28. Deppen SA, Liu E, Blume JD et al. Safety and efficacy of 68Ga-DOTATATE PET/CT for diagnosis, staging and treatment management of neuroendocrine tumors. J Nucl Med 2016;57:708–714.

29. Jiao Y, Shi C, Edil BH et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011;331:1199–1203.

30. Mariniioni I, Kurrer AS, Vassella E et al. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology 2014;146:453–460.

31. Yachida S, Vakiani E, White CM et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol 2012;36:173–184.

32. Ohmoto A, Rokutan H, Yachida S. Pancreatic neuroendocrine neoplasms: Basic biology, current treatment strategies and prospects for the future. Int J Mol Sci 2017;18:143.

33. Rekhtman N, Pietanza MC, Hellmann MD et al. Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non–small cell carcinoma-like subsets. Clin Cancer Res 2016;22:3618–3629.

34. Rinke A, Müller HH, Schade-Brittinger C et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J Clin Oncol 2009;27:4656–4663.

35. Caplin ME, Pavel M, Cwikla JB et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumours. N Engl J Med 2014;371:224–233.

36. Pavel ME, Hainsworth JD, Baudin E et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT 2). A randomised, placebo-controlled, phase 3 study. Lancet 2011;378:2005–2012.

37. Yao JC, Shah MH, Ito T et al. Everolimus for advanced pancreatic neuroendocrine tumours. N Engl J Med 2011;364:514–523.

38. Yao JC, Fazio N, Singh S et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): A randomised, placebo-controlled, phase 3 study. Lancet 2016;387:968–977.

39. Raymond E, Dahan L, Raoul JL et al. Axitinib for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): A randomised, placebo-controlled, phase 3 study. Lancet 2018;391:212–220.

40. Strosberg J, El-Haddad G, Wolin E et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumours. N Engl J Med 2011;364:501–513.

41. Strosberg J, El-Haddad G, Wolin E et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumours. N Engl J Med 2011;364:125–135.

42. Fuentes (sunitinib malate) [package insert]. New York, NY: Pfizer Inc, 2017.

43. Afonit (everolimus) [package insert]. East Hanover, NJ: Novartis Pharmaceutical Corporation, 2017.

44. European Medicines Agency. Everolimus summary of product characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001038/WC500022814.pdf. Accessed December 14, 2017.

45. Pavel ME, Singh S, Strosberg JR et al. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2017;18:1411–1422.

46. Castellano D, Bajetta E, Panneerselvam A et al. Everolimus in neuroendocrine tumours of the gastrointestinal tract and unknown primary. Neuroendocrinology 2018;106:211–220.

47. Hicks RJ, Kwekkeboom DJ, Krenning E et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: Peptide receptor radionuclide therapy with radioiodated somatostatin analogues. Neuroendocrinology 2017;105:295–309.

48. Brabander T, van Zwan WA, Teunissen JIM et al. Everolimus: Long-term efficacy, survival, and safety of [177Lu-DOTA,Tyr3]octreotide in patients with gastroenteropancreatic and bronchial neuroendocrine tumours. Clin Cancer Res 2017;23:4617–4624.

49. Strosberg J, Goldman J, Costa F et al. The role of chemotherapy in well-differentiated gastroenteropancreatic neuroendocrine tumours. Front Horm Res 2015;44:239–247.

50. European Medicines Agency. Sandostatin summary of product characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Sandostatin_LAR_30/WC500169358.pdf. Accessed December 14, 2017.

51. Rubin J, Ajani J, Schirmer W et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999;17:600–606.

52. Vinik AL, Wolin EM, Liyanage N et al. Evaluation of lanreotide depot/autogel efficacy and safety as a carcinoid syndrome treatment (ELECT): A randomized, double-blind, placebo-controlled trial. Endocr Pract 2016;22:1068–1080.

53. Xermelo (telotristat ethyl) [package insert]. The Woodlands, TX: Lexicon Pharmaceuticals, Inc., 2017.

54. Kulke MH, Horsch W, Caplin ME et al. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. J Clin Oncol 2017;35:14–23.

55. Rossi A, Di Maio M, Chioldini P et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: The COCIS meta-analysis of individual patient data. J Clin Oncol 2012;30:1692–1698.

56. Niho S, Kenmotsu H, Sekine I et al. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: A multicenter phase II study. J Thorac Oncol 2013;8:980–984.

57. Dreyer C, Couvelard A, Walter T et al. Clinical and biomarker evaluations of sunitinib in patients (pts) with advanced well-differentiated grade 3 (G3) and poorly differentiated neuroendocrine neoplasms (PD-NEN). J Clin Oncol 2016;34(suppl 4):274a.